Bevacizumab

Human IgG1 kappa

Flow cytometric analysis of 1X10⁶ Hela cells with Bevacizumab (HY-P9906, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

Immobilized VEGF165 Protein, Human (HY-P7110A) can bind Bevacizumab. The EC₅₀ for this effect is 5.34 ng/mL.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Dec 24;10(1):417. [Abstract]

Customer Validation
Treatment of PC9-BM LCN2-high BM-bearing mice with SH4-54 (10 mg/kg, intraperitoneally, twice per week), Bevacizumab (10mg/kg, intraperitoneally, twice per week), or a combination of both significantly suppressed tumor progression and prolonged overall survival.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

Customer Validation
Atezolizumab (4 mg/kg; i.v.) + Bevacizumab (1 mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Collected tumor tissues of mice at the end of treatment in different groups.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 18;16(1):10096. [Abstract]

Customer Validation
Atezolizumab (4mg/kg; i.v.) + Bevacizumab (1mg/kg; i.v.), every other day for 14 days (G4 group) in PDX subcutaneous mouse model. Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45⁺ cells), anti-CD68/CD80-stained macrophages (gated on CD45⁺ cells),anti-HLA-DR/CD11c-stained DCs (gated on CD45⁺ Lin-1^- T cells), and anti-CD3/CD8-stained T cells (gated on CD45⁺ cells) in tumor tissues after different treatments (n = 5 independent mice).

Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

Customer Validation
Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) significantly reversed the upregulatory effect of TQHXD and HXHY on VEGFA protein in MCAO rats.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Brain Res. 2026 Jan 1:1870:150069. [Abstract]

Customer Validation
Bevacizumab (Anti-VEGFA) (HY-P9906) (15 mg/kg; i.p.; once every other day for one week) effectively antagonized the inherent pro-angiogenic effects of TQHXD and HXHY in MCAO rats.

Bevacizumab purchased from MedChemExpress. Usage Cited in: J Clin Oncol. 2024 Oct 30:JCO2401266. [Abstract]

Customer Validation
Tumor-bearing mice were treated with vehicle, Onvansertib, and/or Bevacizumab (intraperitoneally, 5 mg/kg for SW620 and HCT116, 1 mg/kg for LoVo, twice a week) for 30-33 days.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

Customer Validation
Transwell assays showing that Bevacizumab (200 ng/mL, 12 h) failed to inhibit the migration of HUVECs treated with recombinant PTN protein. Unpaired t test; **, P < 0.01; ****, P <0.0001.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Cancer Res. 2024 Jun 4;84(11):1781-1798. [Abstract]

Customer Validation
Tube formation assays showed that Bevacizumab (200 ng/mL) failed to inhibit the tube formation of HUVECs induced by recombinant PTN protein.Unpaired t test; ***, P <0.001; ****, P <0.0001.

Bevacizumab purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):619-638. [Abstract]

Customer Validation
VEGFA IHC staining in control and ATL-I (80 μM or 160 μM)-treated Matrigel plugs. Quantification of vegfa-positive cells. Scale bar: 100 μm. In the present set of experiments, Bevacizumab (50 ng/ml) was used as the positive control.